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Risk prediction algorithms for coronary heart disease (CHD) are recommended for clinical 
use. However, their predictive ability remains modest and the inclusion of genetic risk may 
improve their performance.   
Methods : 
QRISK2 was used to assess CHD risk using conventional risk factors (CRFs). The performance 
of a 19 single nucleotide polymorphism (SNP) gene score (GS) for CHD including variants 
identified by genome-wide association study and candidate gene studies (weighted using 
the results from the CARDIoGRAMplusC4D meta-analysis) was assessed using the second 
Northwick Park Heart Study (NPHSII) of 2775 healthy UK men (284 cases). To improve the 
GS, five SNPs with weak evidence of an association with CHD were removed and replaced 
with seven robustly associated SNPs - giving a 21 SNP GS.  
Results : 
The weighted 19 SNP GS was associated with lipid traits (p<0.05) and CHD after adjustment 
for CRFs, (OR=1.31 per standard deviation, p=0.03). Addition of the 19 SNP GS to QRISK2 
showed improved discrimination (area under the receiver operator characteristic curve 0.68 
v 0.70 p=0.02), a positive net reclassification index (0.07, p=0.04) compared to QRISK2 alone 
and maintained good calibration (p=0.17). The 21 SNP GS was also associated with CHD 
after adjustment for CRFs (OR=1.39 per standard deviation, 1.42x10-3), but the combined 
QRISK2 plus GS score was poorly calibrated (p=0.03) and showed no improvement in 
discrimination (p=0.55) or reclassification (p=0.10) compared to QRISK2 alone.  
 
Conclusion :  








While a large proportion of coronary heart disease (CHD) events are preventable (1, 2), CHD 
remains a common cause of death worldwide. Therefore, predicting those at highest risk of 
developing the disease to target with lifestyle/therapeutic interventions is an important 
public health consideration. To take advantage of the combined knowledge of how 
conventional risk factors (CRFs) predispose individuals to CHD, risk scores have been 
developed. The first such score was derived from data collected as part of the prospective 
Framingham study (3) - referred to as the Framingham score. While the score showed good 
predictive ability in some cohorts similar to that from which it was derived (4, 5), it was 
found to overestimate risk in other ethnic groups (6) and in other populations of European 
ethnicity where there was a lower incidence of CHD (7, 8). The development of primary care 
electronic records has enabled risk scores to be derived from large population cohorts. In 
England the QRISK score was derived from the QRESEARCH database, (which contains 1.2 
million individuals) to estimate risk of cardiovascular disease (CVD) (9)) and the most recent 
National Institute for Health and Clinical Excellence (NICE) guidelines recommend the most 
recent version of this tool (QRISK2) for clinical use (10).  
The majority of cases of CHD come from individuals assigned with average risk using the CRF 
risk scores – the so-called prevention paradox (11). When use of QRISK2 (2010 version) was 
validated with data from the health improvement network, 14% of men and 6% of women 
were identified as being at high risk (as determined by the guidelines at that time). This 
captured 40% of the cardiovascular events in men and 26% of the cardiovascular events in 
women (12). This leaves scope for refinement of the risk score to discriminate between 
those who do and do not go on to develop CVD. In addition, the inclusion of a number of 
additional risk factors for CHD not currently included has been proposed such as 
inflammatory markers (13), lipoprotein(a) (14) and genetic information.  
It has thus far been unclear whether it is beneficial to include an estimate of genetic risk in 
CHD risk prediction. The Joint British Societies’ consensus recommendations for the 
prevention of CVD (JBS3) did not advocate its use, concluding that the available evidence 
showed risk prediction tools including genetic information performed more poorly than CRF 
based tools (15). This has been underlined by the relatively disappointing performance of 
risk scores including gene scores (GSs) comprised of the variants identified in the 
CARDIoGRAMplusC4D meta-analysis of genome-wide association studies (GWASs) (16). 
Assessment in the prospective Rotterdam study (17) and the University College, London 
School of Hygiene and Tropical Medicine, Edinburgh and Bristol (UCLEB) consortium data 
(18)) found only a limited benefit in the population-wide inclusion of the GS in risk 
prediction, although improvements in both discrimination and reclassification were 
observed in a meta-analysis of six Swedish prospective cohorts (19) and the Malmo Diet and 




In 2007 we started to develop a multi-single nucleotide polymorphism (SNP) panel using 12 
SNPs in candidate genes that, when used in combination with the Framingham classical risk 
factor algorithm in a cohort of ~2700 middle-aged men from the UK (NPHSII), had the 
potential to identify individuals at high future risk of CHD (21). We next showed that, in this 
same cohort, the addition of a single SNP from the first GWAS CHD locus identified on 
chromosome 9p21, improved the classical risk factor AROC by 3% but that this effect was 
not statistically significant (22). By modelling, we estimated that an additional three SNPs 
with similar risk size and risk allele frequencies would be needed to have a significant 
improvement. We therefore developed a 19 SNP GS and found it to be of potential clinical 
utility in the same NPHSII cohort (23). The GS comprised the 9p21 SNP plus six other GWAS 
loci identified at that time, supplemented by 12 common SNPs in candidate genes where 
published meta-analyses, mainly of case-control studies, had demonstrated robust albeit 
modest risk effects. The risk allele frequencies for these SNPs varied between 0.01 to 0.99 
and the published odds ratios from 1.06-1.92 (see table 1 in reference 21 and Table 1 
below). However in the meta-analyses of large consortium data sets such as 
CARDIoGRAMplusC4D the odds ratios for several of the included SNPs had reduced and in 
some cases had become non-significant, and the use of these more robust risk estimates 
should improve the clinical utility of the gene score. In addition, replacing those SNPs which 
have non-significant CHD risk effects with SNPs with larger risk effects should also improve 
clinical utility. 
Thus, the aim of the current study was firstly to assess if the performance of the 19 SNP GS 
could be improved by updating the weightings, using the more accurate effect sizes derived 
from the CARDIoGRAMplusC4D GWAS meta-analysis (16). Secondly, we sought to 
investigate the relationship between the updated gene score and CHD CRFs.  Thirdly, we 
assessed the use of the combined CRF plus GS scores in CHD risk prediction to determine if 
including the 19 SNP GS could provide any additional clinical utility.  Finally, we assessed if 
removing SNPs not found to be associated with CHD in the CARDIoGRAMplusC4D meta-




The Second Northwick Park Heart Study (NPHSII) 
NPHSII is a prospective CHD study of approximately 3000 men which has been described 
previously (24). Briefly, middle-aged men (50-64) were recruited from 9 general practices in 
the UK.  Anyone with a history of CHD was excluded. There was a median of 13.5 years 
follow-up. CHD was defined as acute myocardial infarction (MI), silent MI or undergoing 
coronary surgery. Family history of early CHD was collected as reported previously (25). All 
subjects gave written informed consent and the study had ethical approval from the 
national research ethics service (NRES) Committee London-Central. The baseline 
characteristics have been published previously by CHD outcome in follow-up (23). The 2012 
version of QRISK2 was calculated.  
Genotyping:  
For the 19 SNPs previously genotyped and published (23), some had been  genotyped using  
restriction length polymorphism methods (21) but the majority of SNPs, as well as the seven 
SNPs added in this study, were genotyped using Taqman (Applied Biosystems, Life 
Technologies, Carlsbad California, USA) assays and KASPar (LGC. Teddington, Middlesex, UK) 
assays. The call rate for each genotype is listed in Table 1.  
 
Gene Score 
For the 19 SNP GS (23), we updated the weightings to the beta-coefficients determined in 
the CARDIoGRAMplusC4D meta-analysis as previously described (26). The values used are 
given in Table 1. Three SNPs (rs7412 and rs429358 in APOE and rs11591147 in PCSK9) were 
not included in this analysis and therefore the effect size from the most recent meta-
analysis concerning the relationship between these SNPs and CHD was used as indicated. 
The SNPs included in the 19 SNP GS (and the 21 SNP GS) are shown in Table 1.  
Statistical analysis 
Use of an earlier version of the 19 SNP GS in NPHSII has been published (26). We updated 
the weightings to the beta-coefficients determined in the CARDIoGRAMplusC4D meta-
analysis as previously described (26). Briefly, unweighted gene scores were determined by 
simply counting the number of risk alleles present for each SNP for each individual, while 
the weighted scores were calculated for each individual by multiplying the number of risk 
alleles carried for each SNP by the published effect size for that SNP and summing the 
values for all SNPs to obtain the individual’s gene score. Numeric variables were compared 
using t-tests and categorical variables were compared using chi-squared tests. Regression 
was used to assess the relationship between the GS and CHD and CRFs. Calibration of the 
combined (CRF plus GS) risk scores was assessed with the Hosmer-Lemeshow test (using ten 
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degrees of freedom). The ability of the risk scores to discriminate between those who did 
and did not have an event was assessed the area under the receiver operator characteristic 
curve (AUC).  values were compared using DeLong’s test. Reclassification of individuals in 
different risk categories with the addition of the GS to a CRF risk score was assessed using 
the net reclassification index (NRI). Where imputation was used, this was performed by 
assigning the missing genotyping as the mean number of alleles for that particular SNP, only 
in those NPHSII participants with a single missing genotype.  A p-value<0.05 was considered 





The baseline characteristics of the NPHSII cohort are presented in Table 2. As expected, the 
men who developed CHD during ten-year follow-up were older, had higher BMI, higher 
systolic blood pressure, higher total cholesterol, low density lipoprotein (LDL) cholesterol, C-
reactive protein (CRP) and fibrinogen and a higher proportion were smokers at baseline. 
Furthermore, those who developed CHD had a higher ten-year CHD risk as calculated using 
the Framingham risk score and those who developed CVD had a higher ten-year CVD risk as 
calculated using the QRISK2 score.   
Association of GS with CHD  
The mean GS was higher in those who went to develop CHD and CVD during the ten-year 
follow-up, (as shown in Table 3). Both the un-weighted and weighted GSs were associated 
with CHD after adjustment for age (OR=1.39 per standard deviation (sd) of GS (95% 
confidence intervals (Cis) 1.14-1.70 p=1.37 x10-3) and OR=1.46 per sd of GS (95% CIs 1.04-
1.80 p=2.39 x10-4 respectively), with the weighted score showing a stronger association. This 
association remained only for the weighted score when the model was adjusted for the 
CRFs age, cholesterol, high density lipoprotein (HDL)-cholesterol, systolic blood pressure, 
smoking and family history, OR=1.31 per sd of GS (95% 1.03-1.68), p=0.03. 
Association of GS with CRFs for CHD  
The 19 SNP GS was associated with four lipid traits, cholesterol, LDL-cholesterol, 
apolipoprotein-B, and lipoprotein (a) (all p<0.05) as shown in Table 3A. It was also 
associated with family history of CHD (p=0.03), with 39% of these of the in top quartile of 
gene score having a family history of CHD compared to 31% in the bottom quartile.   
The GS in CHD Risk Prediction 
We assessed two CRF scores for CHD in NPHSII – the Framingham score and QRISK2. While 
QRISK2 was well calibrated (p=0.10, Figure 1B), the Framingham score generally 
underestimated risk resulting in poor calibration (p=4.21x10-5, Figure 1A). Therefore, further 
analysis was performed with QRISK2 only. Complete data (ten-year CVD outcome, 
genotyping and QRISK2 score) was available for 1213 NPHSII participants for QRISK2 plus 19 
SNP GS. This combined QRISK2 plus 19 SNP GS score remained well calibrated (p=0.17, 
Figure 1B) and showed an improvement in discrimination compared to QRISK2 alone (AUC 
0.68 v 0.70 p=0.02, Figure 3). The addition of the 19 SNP GS to QRISK2 also resulted in 
improved risk classification in the group who developed CHD, giving a positive NRI 




Addition of extra SNPs 
To assess if the gene score could be improved, we removed five SNPs which had shown little 
evidence of an association with CHD in the CARDIoGRAMplusC4D meta-analysis (p>0.01) 
(Table 1). We then selected seven SNPs from those robustly associated with CHD in the 
CARDIoGRAMplusC4D. The SNPs were ranked according to risk allele frequency multiplied 
by the beta-coefficient (Supplementary Table 1). The top seven SNPs, discounting those in 
loci already included in the GS (Table 1), were then genotyped in NPHSII and added into the 
GS to create a 21 SNP GS. 
The weighted 21 SNP GS was higher in those who went on develop CHD (3.04 (n=862) v 3.16 
(n=83), p=2.6x10-4) and CVD (3.05 (n=855) v 3.15 (n=99), p=4.41x10-4). The gene score was 
associated with CHD OR=1.40 per sd of GS (1.15-1.69) p=7.31x10-4 and remained so after 
adjustment for age, cholesterol, HDL-C, smoking, systolic blood pressure and family history 
of CHD, OR=1.59 per sd of GS (1.22-2.10) p=8.40x10-4.  As with the 19 SNP GS, the 21 SNP GS  
was associated with lipid traits, cholesterol, LDL-cholesterol,  and lipoprotein (a) (all p<0.05) 
as shown in Table 3B.  
When the 21 SNP GS was combined with QRISK2, this combined score remained well-
calibrated (p=0.11) and showed improved discrimination compared to QRISK2 alone (AUC 
0.66 v 0.69, p=0.04, Figure 2). However, while the NRI was positive, it was not statistically 
significant (NRI=0.08, p=0.10). One possibility for this could be loss of power due to sample 
drop-out, since only 954 participants had genotype data for all 21 SNPs as well as QRISK2 
and follow-up data. To increase the number of participants that could be included in the 
analysis and as the data was considered to be missing at random, the missing genotype for 
those with only one missing genotype were imputed and the 21 SNP GS calculated.  
In the imputed data set, the gene score was similarly associated with CHD (OR=1.38 per sd 
of GS (1.16-1.63) p=1.31x10-4) and remained so after adjustment for age, cholesterol, HDL-C, 
smoking, systolic blood pressure and family history of CHD, OR=1.39 per sd of GS (1.14-1.71) 
p=1.42x10-3. There was a significant association between the imputed 21 SNP GS and 
QRISK2 (p=0.03), which was not the case with the un-imputed data set, (again probably 
reflecting the lower power in the unimputed data set). However, when the combined 
QRISK2 plus imputed 21 SNP GS score was calculated using this data (n=1736) the score was 
poorly calibrated (p=0.03) and did not show an improvement in discrimination (AUC 0.69 v 





In this study we assessed the relationship between a 19 SNP GS and CHD in a cohort of 
middle-aged men from the UK. The SNPs were originally been chosen from meta-analyses of 
candidate gene studies and early GWASs (23). In 2013 the CARDIoGRAMplusC4D consortium 
published meta-analyses of GWAS results based on >130,000 controls and >60,000 cases 
(16) which should provide a much more robust estimate of the effect size pertaining to each 
CHD risk loci than was previously available. Therefore the weightings used in the 19 SNP GS 
were updated to those effect sizes determined in the CARDIoGRAMplusC4D meta-analysis. 
A combined risk score of QRISK2 plus the updated 19 SNP GS was found to have good 
calibration and to show improved discrimination between those who did and did not 
develop CVD in follow-up and improved reclassification in those who developed CVD, 
compared to the QRISK2 score alone. Therefore, our results including this GS in an 
estimation of CHD risk (along with QRISK2) could have clinical utility in the UK population. 
This result is likely to be relevant to subjects of similar ethnic origin such as white Caucasian 
populations in North America, Austalasia, and Europe, but extension to other ethnic groups 
requires additional study.   
Having improved the performance of the 19 SNP GS by updating the weightings used in the 
calculation of the GS, we then assessed a 21 SNP GS created from the 19 SNP GS. The five 
SNPs with the weakest evidence of an association with CHD in the CARDIoGRAMplusC4D 
meta-analysis removed and replaced with the top seven ranked variants in loci not already 
included. Of the seven added SNPs three have been found to be associated with blood 
pressure traits (GUCY1A3 (enzyme catalysing conversion of GTP to GMP, activated by nitric 
oxide) rs7692387, CYP17A1 (enzyme of the cytochrome P450 superfamily, involved in 
steroid biosynthesis) rs12413409, ZC3CH1 (protein involved in the regulation of mitosis) 
rs11556924) and one with lipid traits (LDLR (encodes the LDL receptor) rs1122608)(16).It 
was expected that the addition of these robustly associated loci would more accurately 
reflect an individual’s genetic risk of CHD and that further improve the performance of the 
combined QRISK2 plus GS risk score compared to the QRISK2 score alone. This appeared to 
be the case, although, possibly because of the reduced numbers available with complete 
genotype data, the NRI, which increased from 0.07 to 0.08, was not statistically significant. 
We expected that with increased numbers achieved by imputation of missing SNP data we 
would detect a statistically significant positive NRI and maintain good calibration while 
showing improved discrimination compared to QRISK2 alone. However, using the imputed 
data set, the combined QRISK2 plus imputed 21 SNP GS score showed poor calibration and 
no improvement in discrimination or NRI compared to QRISK2 alone. Further analysis found 
a statistically significant association between the 21 SNP GS and QRISK2 in the imputed data 




The results also show that QRISK2 was better at predicating cardiovascular outcome in 
NPHSII compared to the Framingham score, with the Framingham score overestimating risk 
in NPHSII. This is consistent with the literature where even the NICE-adjusted Framingham 
risk equations have been found to overestimate ten-year CHD risk in the UK population, 
particularly in men (12). The superior performance of QRISK2 compared to the Framingham 
score is unsurprising given that QRISK2 was derived from a  very large British cohort while 
Framingham was developed from the Framingham study based in Massachusetts, USA (3, 
12, 27). 
The improved performance of the 19 SNP GS with the updated weightings (as detailed in 
(23)) demonstrates that the effect sizes derived from the CARDIoGRAMplusC4D analysis 
more accurately reflect the impact of the SNPs CHD risk. All of the updated weightings were 
lower, indicating that the original effect sizes were inflated. This is a common problem in 
genetic studies (28). However, it has been suggested that due to the nature of case selection 
in GWASs, many of the variants identified in the CARDIoGRAMplusC4D meta-analysis are 
actually associated with CHD survival rather than an incident CHD event itself. This is 
supported by data from both the Rotterdam study and UCLEB consortium, where the gene 
score was more strongly associated with prevalent rather than incident disease (17), (18)). 
This indicates that the weightings used may not accurately reflect the impact of each variant 
on incident CHD risk and thus effect sizes obtained from a prospective cohort should be 
used. This strategy was used by Ganna, Magnusson et al. and a better performance was 
observed with the inclusion of the GS (19). This issue is likely to be more pertinent for the 
CARDIoGRAMplusC4D SNPs whereas the majority of SNPs included in the 19 SNP GS have a 
clear mechanism of action to impact CHD and rather than purely CHD survival. This may 
partly explain the relatively strong performance of the updated 19 SNP GSs in NPHSII 
compared to the relatively poor performance of the CARDIoGRAMplusC4D GSs in much 
larger studies. Ultimately, a large-scale well-powered prospective study is required to 
alleviate the problem of survival bias in genetic association studies. If such data became 
available this could be used to provide the weights for the GS SNPs and this should improve 
its performance.  
It not surprising that the 19 SNP GS is associated with a number of lipid traits (cholesterol 
measures, apolipoprotein-B, lipoprotein (a)) given that a number of SNPs in the GS are 
located in genes encoded proteins involved in lipid metabolism. The 19 SNP GS was 
associated with CHD even after adjustment for total cholesterol indicating that a higher 19 
SNP GS value can reflect lifelong genetically raised total cholesterol, which will confer a 
higher risk of CHD than can be reflected by a single point measurement of total cholesterol 
in later-life. Furthermore, the maintenance of the association between the 19 SNP GS and 
CHD despite the inclusion of the family history of CHD in the model suggests that these two 
related measures can provide information concerning different aspects of CHD risk.  
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This work has a number of limitations. One aim of our work is to identify a minimum SNP 
data set that will have clinical utility in CHD risk stratification. With more than 53 CHD SNPs 
now identified we chose to rank SNPs by the product of their European  risk allele frequency 
and reported odds ratio, and examined the improvement achieved using only the top seven.  
While it is possible that the addition of SNPs who rank below these seven may improve 
clinical utility, the data suggest this improvement is at best likely to be modest, as 
demonstrated in the study using all 53 SNPs (18). A second limitation is that all of the 
participants of NPHSII are male and with a mean age of 56 years represent a group where 
CHD is highly prevalent and where intervention to reduce future risk is recommended. It is 
known that the pathogenesis of atherosclerosis is different between the sexes (29), but 
there is no evidence to suggest the risk variant effect sizes differ between men and women, 
and a subgroup analysis performed as part of the CARDIoGRAMplusC4D meta-analysis, 
found no trend for different odds ratios in either sex, but it would be ideal to test the GSs in 
a data set with both sexes. Another issue is that QRISK2 is updated annually and we did not 
have access to the most recent version, although the CRFs included are the same. 
Moreover, our cohort was recruited in 1989 and therefore the cardiovascular risk profile of 
this group may differ from that of the UK population now. Indeed, one of the reasons 
suggested for the overestimation of CHD risk by Framingham score is that the data it was 
derived from was collected at the time of peak cardiovascular risk in that community. 
However, this time-lag is inevitable in a prospective study and ultimately the benefits 
(particularly in minimising bias) outweigh the disadvantages.  
 
The clinical utility of the GS described here depends on the context, as pointed out recently 
for T2D (30). If a clinician is trying to predict the risk score of 65 year old men, the GS is 
irrelevant, since the vast majority will qualify for statin treatment under QRISK2 threshold 
set in the current NICE guidelines (31). By contrast for the age of 40 or 30 or even at birth 
the situation might be different. For example, at birth there will almost never be CRFs of 
concern but the GS can point much further in the future, suggesting that this individual 
might need to see a doctor when in their late thirties instead of past 40, as may otherwise 
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Table 1: SNPs  included in the 19 SNP GS and the 21 SNP GS  
SNPs included in the 19 SNP GS  
 
Gene/Locus  SNP Risk 
Allele 
OR OR in 
original 
score 
Frequency p-value* Source Call 
Rate 
APOE* rs7412 C 1.25 0.80** 0.87 -  (32) 97 % 
APOE* rs429358 C 1.06 1.06 0.26 - (32) 97 %  
PCSK9* rs11591147 G 1.39 1.43 0.99 - (33) 85 % 
CDKN2A/9p21* rs10757274a G 1.23 1.29 0.47 1.39x10-
52 
Cplus4D 97 % 
SORT1* rs599839 A 1.11 1.19 0.77 3.8x10-
15 
Cplus4D 96 % 
LPA* rs10455872 G 1.32 1.70 0.06 3.80x10-
13 
CG GWAS 93 % 
MIA3* rs17465637 C 1.14 1.14 0.74 1.36x10-
8 
CG GWAS 92 % 
MRAS* rs9818870 T 1.07 1.15 0.14 2.62x10-
9 
Cplus4D 94 % 
CXCL12* rs1746048b C 1.07 1.17 0.83 1.79x10-
8 
Cplus4D 96 % 
LPL* rs328 C 1.09 1.25 0.91 2.34x10-
4 
CG GWAS 95 % 
DAB2IP* rs7025486 A 1.04 1.16 0.29 2.14x10-
3 
Cplus4D 97 % 
LPL* rs1801177e A 1.10 1.33 0.06 4.04x10-
4 
Cplus4D 87 % 
LPA* rs3798220 C 1.28 1.92 0.01 4.90x10-
5 
Cplus4D 96 % 
APOA5* rs662799 G 1.05 1.19 0.06 0.01 Cplus4D 89 % 
CETP rs708272d C 1.04 1.28 0.56 0.04 CG GWAS 90 % 
ACE rs4341c G 1.01 1.22 0.52 0.43 CG GWAS 98 % 
APOB rs1042031 A 1.01 1.73 0.18 0.80 Cplus4D 96 % 
NOS3 rs1799983 G 1.00 1.31 0.67 0.90 CG GWAS 85 % 
SMAD3 rs17228212 C 1.01 1.21 0.31 0.94 Cplus4D 96 % 
Additional SNPs included in the 21 SNP GS  
 
 
Gene/Locus  SNP Risk Allele OR 
 
Frequency Source Call 
Rate 
GUCY1A3 rs7692387 G 1.13 0.81 Cplus4D 91 % 
PPAP2B rs17114036 T 1.11 0.91 Cplus4D 91 % 
CYP17A1-CNNM2-NT5C2 rs12413409 G 1.10 0.89 Cplus4D 91 % 
LDLR rs1122608 G 1.10 0.76 Cplus4D 90 % 




* Included in both the 19 SNP GS and the 21 SNP GS. aWeighting for rs1333049 (r2=0.88). 
bWeighting for rs501120 used (r2=0.97). cWeighting for rs4343 (r2=0.96). dWeighting for 
rs711752 (r2=1). eWeighting for rs7016529 (r2=1).f tagging rs12526453 (r2=0.90).  All r2 values 
calculated from 1000 Genomes phase 1 EUR data. Data on coronary artery disease / 
myocardial infarction have been contributed by CARDIoGRAMplusC4D investigators and 
have been downloaded from www.CARDIOGRAMPLUSC4D.ORG. **In the original score, the 
protective allele was included rather than the risk allele. OR= odds ratio. Cplus4D = 






















PHACTR1 rs9369640f A 1.09 0.65 Cplus4D 98 % 
ZC3HC1 Rs11556924 C 1.09 0.65 Cplus4D 89 % 
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Table 2 : Baseline characteristics in NPHSII for those who did and did not go on to develop 


























All variables are presented as the mean plus standard deviation except where indicated. 
Categorical variables were compared using chi-squared tests and continuous variables were 
compared using Welch’s t-tests, apart from the Lipoprotein (a), Framingham and QRISK2 risk 
scores (shown as proportions) which were compared using Mann Whitney tests (the median 
and interquartile range are given). *Values were log transformed and geometric mean and 
approximate standard deviation are shown.**QRISK2 values shown are for those who did 



















Age (years) 55.91 (3.42) 56.64 (3.60) 4.12x10-3 
Sex (% Male) 100 % 100 % - 
Smoking  % (n) 25 %  (n=567) 38 % (n=50)  1.90x10-3 
Family history of CHD % (n) 34 % (n=731) 53 % (n=66) 5.68x10-3 
BMI (kg/m2) 26.38 (3.42) 27.19 (3.44) 9.61x10-4 
Systolic Blood Pressure 
(mmHg) 
137.00 (18.59) 144.09 (20.10) 9.68x10-7 
Total Cholesterol (mmol/l) 5.71 (1.01) 6.13 (1.05) 4.79x10-8 
LDL-cholesterol (mmol/l) 3.07 (1.00) 3.48 (0.97) 2.66x10-7 
HDL-cholesterol (mmol/l) 1.72 (0.59) 1.57 (0.53) 2.60x10-4 
Triglycerides (mmol/l)* 1.78 (0.93) 2.02 (1.02) 3.13x10-3 
Apolipoprotein-B (g/l) 0.89 (0.26) 0.97 (0.24) 2.06x10-4 
Apolipoprotein-A1 (g/l) 1.63 (0.32) 1.61 (0.28) 0.22 
Lipoprotein (a)* (g/l) 0.09 (0.03-0.30) 0.13 (0.03-0.30) 0.12 
C-reactive Protein* (mg/l) 267.83 (50.16) 284.65 (49.21) 9.13x10-5 
Fibrinogen *(g/l) 2.75 (3.19) 4.47 (5.18) 3.21x10-5 
Framingham ten-year CHD 
risk 
0.12 (0.07-0.15) 0.17 (0.09-0.21) 4.33x1011-
4 




Table 3A: Association between 19 SNP weighted gene score and CRFs for CHD 
Gene score was divided into tertiles and regression analysis performed. The mean and 
standard deviation are shown for each tertile. *Variable was log transformed and the 
geometric mean and approximate standard deviation are shown, expect for QRISK2 where 
the median and interquartile range are shown (proportions given). **Median and 
interquartile range shown and tobit regression on ln(lpa+1). CHD = coronary heart disease. 














Age (years) 56.5 (3.48) 56.21 (3.51) 56.43 (3.59) 0.73 
Smoking % (n) 26 % (n=120) 28 % (n=129) 30 % (n=138) 0.18 
Family history of CHD % (n) 31 % (n=133) 37 % (n=155) 39 % (n=165) 0.03 
BMI (kg/m2)* 26.30 (3.43) 26.78 (3.49) 26.45 (3.41) 0.51 
Systolic blood pressure 
(mmHg) 138.85 (19.70) 139.97 (19.25) 139.33 (190.34) 0.71 
Total Cholesterol (mmol/l) 5.64 (1.00) 5.81 (0.95) 5.86 (1.01) 5.74x10-4 
LDL-cholesterol (mmol/l) 3.02 (1.02) 3.22 (0.94) 3.28 (0.99) 3.88x10-4 
HDL-cholesterol (mmol/l) 1.69 (0.59) 1.65 (0.54) 1.63 (0.61) 0.15 
Triglyceride *(mmol/l) 1.78 (0.93) 1.83 (0.95) 1.84 (1.00) 0.10 
Apolipoprotein-B (g/l) 0.89 (0.28) 0.91 (0.26) 0.93 (0.26) 0.01 
Apolipoprotein-A1  g/l) 1.61 (0.33) 1.60 (0.29) 1.59 (0.33) 0.50 
Lipoprotein (a)** (g/l) 0.08 (0.02-0.18) 
0.08 (0.03-
0.20) 0.19 (0.04-0.42) 3.68x10
-9 
C-reactive Protein*(mg/l) 3.41 (3.94) 3.28 (3.71) 3.16 (3.67) 0.34 
Fibrinogen *(g/l) 2.73 (5.12) 2.73 (5.07) 2.72 (5.18) 0.69 
QRISK* 0.09 (0.07-0.14) 
0.10 (0.08-
0.14) 0.11 (0.08-0.15) 0.05 
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Table 3B: Association between 21 SNP weighted gene score and CRFs for CHD 
Gene score was divided into tertiles and regression analysis performed. The mean and 
standard deviation are shown for each tertile. *Variable was log transformed and the 
geometric mean and approximate standard deviation are shown, expect for QRISK2 where 
the median and interquartile range are shown (proportions given).**Median and 
interquartile range shown and tobit regression on ln(lpa+1).  CHD = coronary heart disease. 




















Age (years) 56.20 (3.53) 56.18 (3.43) 56.47 (3.62) 0.32 
Smoking % (n) 25 % (n=89) 27 % (n=92) 30 % (n=102) 0.17 
Family history of CHD % 
(n) 33% (n=107) 36 % (n=114) 37 % (n=118) 0.27 
BMI (kg/m2)* 26.12 (3.38) 26.35 (3.32) 26.16 (3.35) 0.87 
Systolic blood pressure 
(mmHg) 138.60 (19.64) 138.50 (18.69) 139.95 (19.22) 0.36 
Total Cholesterol (mmol/l) 5.57 (0.97) 5.75 (0.97) 5.83 (1.02) 4.66x10-4 
LDL-cholesterol (mmol/l) 2.93 (0.95) 3.13 (0.94) 3.18 (1.00) 1.28x10-3 
HDL-cholesterol (mmol/l) 1.70 (0.58) 1.69 (0.61) 1.69 (0.61) 0.81 
Triglyceride *(mmol/l) 1.58 (0.63) 1.57 (0.64) 1.55 (0.76) 0.72 
Apolipoprotein-B (g/l) 0.88 (0.27) 0.89 (0.25) 0.91 (0.25) 0.13 
Apolipoprotein-A1  g/l) 1.62 (0.33) 1.62 (0.32) 1.63 (0.32) 0.65 
Lipoprotein (a)** (g/l) 0.07 (0.02-0.20) 0.07 (0.02-0.24) 0.15 (0.04-0.36) 6.38x10
-6 
C-reactive Protein*(mg/l) 3.11 (3.54) 3.15 (3.61) 2.78 (3.07) 0.23 
Fibrinogen *(mg/dl) 2.73 (5.14) 2.68 (4.82) 2.72 (4.90) 0.72 




Table 4: Reclassification of NPHII participants with the addition of the gene scores to QRISK2  
 
CRFs= conventional risk factors. NRI=net reclassification index. 
Risk Score Reclassifie







d at  
higher risk 
NRI 
(95 % CIs) 
p-value 
QRISK2 + 19 SNP 
GS 
 




CHD 3 114 16 
Event rate 5.56 % 10.76 % 16.00 % 
QRISK2 + 21 SNP 
GS 
 




CHD 4 79 16 
Event rate 8.89 % 9.67 % 17.39 % 
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Figure Legends: Figure 1A: Calibration plot of observed probabilities and predicted 
probabilites of CHD, by decile of risk score for the Framingham score alone and the 
Framingam score plus the 19 SNP GS 
CHD=Coronary heart disease. GS=Gene score. SNP= single nucleotide polymorphism. 
 
Figure 1B: Calibration plot of observed probabilities and predicted probabilites of CHD, by 
decile of risk score for the QRISK2 score alone and the QRISK2 score plus the19 SNP GS 
CHD=Coronary heart disease. GS=Gene score. SNP= single nucleotide polymorphism.  
Figure 2: ROC curves for CRF score alone and with the addition of the 19 SNP GS and 21 SNP 
GS 





Supplementary Table 1 : Top 25 CARDIoGRAMplusC4D CHD risk loci ranked by ln(OR) 
multiplied by RAF 
OR=odds ratio. RAF=risk allele frequency. *Additional SNPs selected for inclusion in the 21 
SNP GS. +SNPs already included in the GS (or in linkage disequilibrium with SNPs that were).  
 
 
Chromosome Lead SNP Gene/Locus OR RAF ln(OR) x RAF 
19 rs445925+ ApoE-ApoC1 1.13 0.9 0.110 
4 rs7692387* GUCY1A3 1.13 0.81 0.099 
9 rs1333049+ 9p21 1.23 0.47 0.097 
1 rs17114036* PPAP2B 1.11 0.91 0.095 
1 rs602633+ SORT1 1.12 0.77 0.087 
10 rs12413409* CYP17A1-CNNM2-NT5C2 1.1 0.89 0.085 
19 rs1122608* LDLR 1.1 0.76 0.072 
13 rs9515203* COL4A1-COL4A2 1.08 0.74 0.057 
9 rs3217992+ 9p21 1.16 0.38 0.056 
10 rs501120+ CXCL12 1.07 0.83 0.056 
6 rs9369640* PHACTR1 1.09 0.65 0.056 
7 rs11556924* ZC3HC1 1.09 0.65 0.056 
8 rs264+ LPL 1.06 0.86 0.050 
13 rs4773144 COL4A1-COL4A2 1.07 0.74 0.050 
6 rs4252120 PLG 1.07 0.73 0.049 
1 rs11206510 PCSK9 1.06 0.84 0.049 
1 rs17464857 MIA3 1.05 0.87 0.042 
1 rs4846525 IL6R 1.09 0.47 0.041 
15 rs7173743 ADAMTS7 1.07 0.58 0.039 
17 rs12936587 RAI1-PEMT-RASD1 1.06 0.59 0.034 
6 rs12205331 ANKS1A 1.04 0.81 0.032 
13 rs9319428 FLT1 1.1 0.32 0.030 
2 rs1561198 VAMP5-VAMP8-GGCX 1.07 0.45 0.030 
12 rs3184504 SH2B3 1.07 0.4 0.027 
8 rs2954029 TRIB1 1.05 0.55 0.027 
